The prime anti-viral cytokine interferon-a (IFN-a) has been implicated in several central nervous system (CNS) disorders in addition to its beneficial effects. Systemic IFN-a treatment causes severe neuropsychiatric complications in humans, including depression, anxiety and cognitive impairments. While numerous neuromodulatory effects by IFN-a have been described, it remains unresolved whether or not systemic IFN-a acts directly on the brain to execute its CNS actions. In the present study, we have analyzed the genes directly regulated in post-IFN-a receptor signaling and found that intraperitoneal administration of mouse IFN-a, but not human IFN-a, activated expression of several prototypic IFN-stimulated genes (ISGs), in particular signal transducers and activators of transcription (STAT1), IFN-induced 15 kDa protein (ISG15), ubiquitin-specific proteinase 18 (USP18) and guanylate-binding protein 3 (GBP3) in the brain. A similar temporal profile for the regulated expression of these IFN-aactivated ISG genes was observed in the brain compared with the peripheral organs. Dual labeling in situ hybridization combined with immunocytochemical staining demonstrated a wide distribution of the key IFN-regulated gene STAT1 transcripts in the different parenchyma cells of the brain, particularly neurons. The overall response to IFN-a challenge was abolished in STAT1 knockout mice. Together, our results indicate a direct, STAT1-dependent action of systemic IFN-a in the CNS, which may provide the basis for a mechanism in humans for neurological/neuropsychiatric illnesses associated with IFN-a therapy.
Introduction
Discovered initially for its anti-viral action, interferon-a (IFN-a) is a key mediator of the innate and adaptive immune response. 1 In addition to its critical roles in host defense, IFN-a has also been demonstrated to have several central nervous system (CNS) effects ranging from increased neuronal excitabilities 2 and regulation of temperature, 3 circadian rhythm 4 and sleep 3 to ingestive behavior 5 and emotion. 6 Despite wide therapeutic application of IFN-a in chronic viral infections and in several types of malignancies, there is mounting evidence that IFN-a is associated with brain damage in several clinical conditions including HIV-associated dementia, 7 CNS lupus 8 and familial Aicardi-Goutieres syndrome. 9 A direct connection between IFN-a and human CNS disorders came from recent clinical observations in which chronic, high-dose IFN-a therapy was frequently found to lead to severe neurotoxicity and neuropsychiatric complications such as agitation, depression, anxiety and memory loss in as high as 30-45% of patients. 10, 11 Depression-and anxiety-like behaviors, associated with disturbances in monoamine neurotransmission 12 following systemic IFN-a treatment, have also been reported in rodents. 6, 13 In search of the molecular basis for neuromodulatory actions, especially neuropsychiatric complications associated with systemic IFN-a, recent positron emission tomography and functional magnetic resonance imaging have recorded metabolic changes from patients undergoing IFN-a therapy in several parts of the brain. 14, 15 However, the site of action of systemic IFN-a remains undefined with regard to its CNS consequences. This issue has been argued for years, and earlier pharmacokinetic studies estimated that only a small fraction (less than 0.2%) of peripherally administered molecules gain access to the CNS. 16, 17 Nevertheless, over the last two decades there have been studies suggesting that systemic cytokines may access the brain and affect brain function by either overcoming the blood-brain barrier through limited diffusion or saturable transport systems 18 or via direct sensory nerve connections from the periphery. 19 Other than its effectiveness for neuroregulatory actions after the intra-cerebral administration of cytokines, 20, 21 there was, however, no specific marker to demonstrate and confirm a direct CNS action for IFN-a following systemic peripheral administration.
Nevertheless, the molecular cascade for IFN-a postreceptor signaling has recently been elucidated. 22, 23 Binding of IFN-a to the common type I IFN (IFN-a/b) receptor (IFNAR) triggers activation of the IFNAR leading to receptor subunit dimerization, and phosphorylation of receptor proteins as well as two transcription factors signal transducers and activators of transcription (STAT1) and STAT2 by members of Janus kinase (Jak) and tyrosine kinase (Tyk) family Jak1 and Tyk2. Phosphorylated STAT1 and STAT2 then form heterodimers, and migrate into the nucleus and associate with another molecule, IFN regulatory factor-9 (also called p48 or ISGF-3g), forming IFNstimulated gene factor 3 (ISGF-3). This biologically active ISGF-3 then interacts with a specific DNA sequence called the IFN-stimulated response element present in the promoter region of type I IFNstimulated genes (ISGs) to activate ISG transcription, resulting in IFN-a-induced gene expression associated with the biological effects of IFN-a. Recent investigations by global gene profiling of IFN-atreated cells have revealed a list of ISGs in hematopoietic cells 24 as well as in primary cultured neurons. 25 Among the most highly expressed genes are IFN-induced 15 kDa protein (ISG15), ubiquitin-specific proteinase 18 (USP18), IFN-induced 10 kDa protein (IP-10 or CXCL10), STAT1, and IFN-induced guanylate-binding protein 3 (GBP3).
To define a possible direct CNS action by peripheral systemic IFN-a, we took a new approach and used the IFN-stimulated genes as an indicator for a direct IFN-a action in the brain following peripheral IFN-a administration. We found that intraperitoneal (i.p.) injection of mouse IFN-a, but not human IFN-a, activated the expression of these genes in different areas of the brain in a temporal profile similar to those in peripheral organs. This IFN-a-induced transcriptional response was totally STAT1-dependent. Distribution studies revealed that STAT1 transcripts were expressed highly in the neurons and also found to be colocalized with other types of brain parenchyma cells. Therefore, we conclude there is a direct effect of systemic IFN-a on the CNS and neurons. These findings have implications for understanding the potent and often adverse actions of IFN-a in human neurological and neuropsychiatric disorders.
Materials and methods

Animals
Eight to 10-week-old male C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). STAT1 knockout mice were purchased from Taconic (Germantown, NY, USA). All animals were housed in a temperature-controlled vivarium on a 12-12 light cycle (lights on 0700 h) at 21-231C with free access to food and water. Mice were assigned to experimental groups randomly. The handling of mice and experimental procedures were conducted in accordance with the National Institutes of Health (NIH) guidelines for animal care and use and approved by University of Missouri-Kansas City institutional animal care and use committee.
Materials and experimental procedures
Both recombinant mouse IFN-aA and human IFN-aA free of carrier proteins were obtained from PBL Biomedical Laboratories (New Brunswick, NJ, USA). Recombinant mouse CXCL10 (IP-10) was purchased from PeproTech (Rocky Hill, NJ, USA). Mice were injected i.p. with 0.1 ml of freshly prepared, pyrogenfree phosphate buffered saline (PBS) (0.1 M, pH 7.4) or the recombinant protein in PBS. Following injection, mice were killed by decapitation and the brain, liver and spleen were removed, and fixed or snap-frozen for further analysis as described below. For sample collection, all mice were killed between 1230 and 1630 h.
RNase protection assay
Poly (A þ ) RNA was extracted from freshly dissected snap-frozen brain, spleen and liver using oligo-dT (Ambion, Austin, TX, USA). The RNase protection assay (RPA) probe for dsRNA-dependent protein kinase R (PKR), USP18, STAT1, ISG15, GBP3, IP-10, IFN-a1, IFN-b and IFN-g were prepared and the RPA was performed as described previously. 25, 26 Briefly, 32 P-UTP (Amersham Biosciences, Piscataway, NJ, USA) labeled ribosomal antisense RNA probes were hybridized with the RNA extracted from dissected tissues. After RNase treatment, undigested probes were extracted, precipitated and separated on 5% acrylamide sequence gel. Finally, a Kodak X-ray film was exposed to dried gel at À801C and developed to visualize and quantify the separated radioactive protected fragments. A probe for the ribosomal protein L32 was included as an internal control for RNA loading. For quantification, densitometric analysis of each band was performed on scanned autoradiographs using NIH Image 1.62 software. 26 In situ hybridization and immunocytochemistry Following perfusion with 4% paraformaldehyde in 0.1 M phosphate buffer, brains were removed and fixed overnight in ice-cold 4% paraformaldehyde in phosphate buffer (pH 7.4). Paraffin-embedded sagittal sections (8 mm) were prepared for in situ hybridization. A 33 P-labeled cRNA probe transcribed from the linearized STAT1 plasmid employed in the RPA described above was used for in situ hybridization as described previously. 27 For dual labeling, in situ hybridization was combined with immunohistochemistry using cell marker-specific antibodies to identify astrocytes (anti-GFAP; Dako Corp., Carpinteria, CA, USA), T lymphocytes (anti-CD3; Dako Corp.) and microglia (lectin from Lycopersicon esculentum; Sigma-Aldrich, St Louis, MO, USA), respectively. Bound antibody was detected using Vectastain ABC kits (Vector Laboratories, Burlingame, CA, USA) and 
Statistical analysis
All data are presented as the mean 7s.e.m. Twogroup data were analyzed using two-tailed unpaired Student's t-test. For time-course and dose-response studies, the data were analyzed with one-way analysis of variance followed by Dunnett's t-test. Statistical significance was defined at p0.05 levels.
Results
Rapid stimulation of IFN-stimulated genes in the brain and peripheral organs following intraperitoneal IFN-a injection.
To assess a possible direct action of systemic IFN-a on the brain, a murine model was developed for peripheral administration of IFN-a by i.p. injection. The dose for IFN-a treatment was based on previous studies carried out both in humans and in mice. In humans, as an effective therapy for cancers and chronic viral infection, the doses of IFN-a therapy range from 3.0 Â 10 6 to 2.0 Â 10 7 IU (international units)/patient (which is about 6.7 Â 10 4 to 2.7 Â 10 5 IU/kg body weight). 28, 29 In mice, behavioral studies reveal the effectiveness of doses of IFN-a at 6 Â 10 4 to 2 Â 10 6 IU/kg of body weight. 30, 31 We analyzed the expression of several prominent ISGs PKR, USP18, STAT1, ISG15, GBP3 and CXCL10 (formerly named IP-10) identified from recent geneprofiling studies of IFN-a-treated cell cultures. 24, 25 While all the ISGs, except CXCL10, were detectable by the RPA in normal adult brain, time-course studies on the expression of these ISGs revealed that peripheral administration of mouse IFN-a induced a rapid stimulation of all the ISGs analyzed except the CXCL10 gene in the brain (Figure 1) . Expression of these genes was significantly increased as early as 2 h, and peaked around 8 h, before returning to basal levels at 24 h after i.p. injection of 10 000 IU of recombinant mouse IFN-a (which is about 3 Â 10 5 IU/kg for a 35-g mouse). However, in contrast to mouse IFN-a, 100 000 IU of human IFN-a (as a control group for mouse IFN-a), a dose which is 10 times that of the mouse IFN-a, had no stimulatory effect on the expression of these IFN-regulated genes (Figure 1) , consistent with the species-restricted activity of IFN-a. 32, 33 Very similar results were obtained in two other experiments. Moreover, as expected, heat inactivation (1001C for 10 min) completely abolished the stimulatory effect of the IFN-a on IFN-regulated gene expression (data not shown), excluding contamination by endotoxin as a possible causative factor.
The temporal expression of the same set of ISGs in the liver from these mice was also analyzed (Figure 2) , and then compared with the profile detected in the brain. A strikingly similar expression pattern for STAT1, ISG15 and GBP3 genes was found between the liver and brain, with significantly increased levels at 2 h after IFN-a injection, which peaked around 8 h before returning to preinjection levels at 24 h following treatment (Figure 2 ). The temporal profiles of PKR and USP18 expression in the liver are, however, different from those observed in the brain following IFN-a administration. The peak PKR and USP18 expression was reached around 4 h in the liver after IFN-a injection. In addition, i.p. injection of IFN-a also caused a rapid activation of CXCL10 transcription in liver with a peak level of expression around 2 h following the treatment. The same set of ISGs were also stimulated in the spleen by i.p. IFN-a treatment with similar temporal kinetics as found in liver (data not shown). To determine whether CXCL10 mediates the stimulation of IFN-regulated genes in the brain by systemic IFN-a treatment, we found that i.p. injection of CXCL10 (1.0 mg/mouse) had no regulatory effect on the expression of the genes analyzed either in the brain (Figure 3) or the peripheral organs (data not shown). To test a possible de novo synthesis of type I IFN inside the brain subsequent to the peripheral IFN-a treatment, we then analyzed the expression of several interferons including two major type I interferons IFN-a1 and IFN-b and none of these genes was detected by the RPA both in the peripheral tissue and the brain (not shown).
To characterize further the response to peripherally administered mouse IFN-a in the brain and peripheral tissues, a dose-response study was performed. Compared with controls, IFN-a treatment dramatically increased the expression of the same ISG set in the brain, even at the lowest dose (600 IU/mouse) of IFN-a injected (Figure 4, upper panel) . Similar to those found in the brain, the transcriptional stimulation for the same ISG set in liver and spleen was significantly activated by i.p. administration of IFN-a, also in a dose-dependent manner (data not shown). We evaluated possible differences between a single IFN-a injection and repeated IFN-a administered every other day for a total of seven injections. Here we found that the expressional amplitude of these genes attained after multiple IFN-a administrations was comparable to that by a single IFN-a injection ( Figure  4, lower panel) . Taken together, our results indicate a direct IFN-a action in the brain when IFN-a is administered by systemic i.p. injection. In addition, the brain is highly sensitive and responsive to peripheral IFN-a treatment similar to peripheral tissues.
Cerebral localization of the IFN-stimulated gene transcripts activated by i.p. IFN-a
To determine the regional and cellular distribution of the enhanced ISG transcripts, in situ hybridization for the STAT1 gene, which codes for a key transcription factor in type I IFN signaling was performed on paraffin-embedded sections of mouse brain from mice i.p. injected with IFN-a. As expected based on the results of the RPA, STAT1 expression was dramatically increased and STAT1 transcripts were widely expressed throughout the brain, with highly expressed STAT1 transcripts in a number of brain regions after systemic IFN-a treatment, including hippocampus (Figure 5a , arrow) and cerebellum ( Figure 5a, arrow head) . Under dark-field microscopy of the emulsion-developed brain section, STAT1 transcripts were also found localized mainly in the dentate gyrus of the hippocampal formation ( Figure  5d , arrow) and the Purkinje and granular layers of the cerebellum (Figure 5e , arrow head), respectively. In addition to a high STAT1 expression by neurons in the hippocampus and cerebellum, combined in situ hybridization with Nissl staining revealed that STAT1 transcripts were expressed in a large number of neurons throughout the brain ( Figures 5 and 6b,  arrows) . Moreover, dual-labeling in situ hybridization with immunohistochemistry showed that STAT1 transcripts were also found in choroidal/ependymal epithelia (Figure 6f Absence of an ISG response to peripheral IFN-a in STAT1-deficient mice Recent studies reported the involvement of alternative pathways other than JAK/STAT in IFN-a signaling. 34 To assess the role of the JAK/STAT pathway in the expression of the IFN-regulated genes as well as IFN-a-mediated signaling, we performed studies using the same IFN-a treatment in mice with deletion of the STAT1 gene (STAT1À/À). We found that, in contrast to wild-type mice, disruption of the STAT1 gene resulted in complete blockade of the transcriptional response to IFN-a (Figure 7 ). In addition, in the absence of IFN-a treatment, the basal levels of ISG15 and GBP3 expression in brain, liver and spleen were lower in STAT-deficient mice than those from wild type controls (data not shown). This observation is in agreement with previous studies on other interferon-regulated genes. 35 Thus, our data indicate that the transcription factor STAT1, is essential in mediating the stimulation of ISGs following in vivo IFN-a treatment.
Discussion
In the present study, we have provided evidence that systemic IFN-a acts on the brain, activating type I IFN receptors and stimulating the expression of IFN-regulated genes. The rapid induction of IFNstimulated genes in the brain by i.p. injection of homologous IFN-a observed in this study indicates that IFN-a circulating systemically can enter the CNS and act in the brain locally. This is supported by an identical temporal pattern of expression for STAT1, ISG15 and GBP3 in the brain and peripheral organs (liver and spleen) following IFN-a administration (Figures 1 and 2 ). In addition, in situ hybridization histochemistry of the STAT1 gene demonstrates highly enhanced STAT1 transcripts colocalized in neurons and other brain parenchyma cells (Figures 5  and 6 ). Considering the dose of IFN-a used (Figure 4 , upper panel), the dramatic ISG stimulation in the brain by i.p. IFN-a challenge suggests that cerebral parenchymal cells are highly sensitive to circulating IFN-a. Together with our previous findings from primary neuronal culture, 25 it is clear that these cells with either mouse IFN-a (6000 IU) or PBS every other day for 2 weeks and brains were collected for RNA extraction 8 h after the last injection (n = 6, **P < 0.01).
are a major component of the cellular response to IFNa in the CNS, which provides a biological basis for the systemic neuropathophysiology of IFN-a. Formerly named leukocyte interferon, IFN-a was the first molecule from the immune system found to communicate with the CNS, 2, 36, 37 and is therefore designed as a 'neuromodulator' for its diverse neuroendocrine and neuroregulatory properties. 38 Ex vivo intracellular recordings have revealed that IFN-a inhibits glutamate-induced excitatory postsynaptic potentials and blocks long-term potentiation by high-frequency titanic stimulation of CA1 hippocampal neurons in rodents. 39 In addition, IFN-a decreases Figure 5 Regional distribution of the transcripts for STAT1 gene in the brains of mice following systemic treatment of IFN-a. Eight hours after injection of IFN-a (6 Â 10 4 IU/mouse) or PBS, mice were perfused and the brains were collected for paraffinembedded sagittal sections. In situ hybridization shows STAT1 RNA transcripts in the dentate gyrus of the hippocampal formation (arrows) and the granular neuron layer of the cerebellum (arrow heads). Original magnifications: Â 1 for (a) and Â 100 for (b-e) (dark field). evoked inhibitory postsynaptic potential amplitude in CA3 pyramidal cells leading to epileptiform bursting. 40 The latter finding is consistent with reports of seizures in children during IFN-a therapy, 41 and seizures observed in transgenic mice with chronic astrocyte-targeted production of IFN-a. 42 In efforts to elucidate the molecular impact of IFN-a on cultured cells, recent global gene-profiling identified a long list of genes that are regulated by IFN-a in hematopoietic cells 24 and neurons, 25 highlighting the potential importance of this innate immune mediator in homeostasis beyond its antiviral and immunoregulatory actions. However, none of these genes identified appears to be directly relevant to neurotransmission and behavioral modulation. In terms of the number of interferon-regulated genes discovered, on the other hand, we are still at an early stage in understanding the function of many IFN-regulated or -stimulated genes as a whole. The roles of different IFN-regulated genes in CNS physiology and pathophysiology such as neurodevelopment, regulation of temperature, sleep, food intake and emotion remain to be explored. In this regard, a recent study found that depletion of a newly identified IFN-stimulated gene USP18 (also named ubiquitin-specific protease 43) , in which expression in brain was highly activated by peripheral IFN-a injection in our study ( Figures  1 and 4) , results in the development of a severe neurological disorder. 43 Despite intense studies and the development of various drug therapies, the etiopathogenesis for common human mental disorders such as affective disorders, anxiety and schizophrenia remains poorly understood. 44, 45 However, recent clinical observations from patients on IFN-a therapy 10, 11 and genetic studies on autoimmune mice 46 suggest a direct link between IFN-a and neuropsychiatric disorders. Therapeutic application of IFN-a presents a wide range of side effects, particularly CNS complications, including depression, anxiety and cognitive abnormalities often leading to the discontinuation of the therapy. The new findings have also renewed interest in the possibility of a causal link between infections and human mental illnesses. In the present study, we have shown a dramatic activation of the genes regulated by IFN-a in the brain after systemic administration of this anti-viral cytokine (Figures 1 and 4) . Our data indicate not only the importance of the biology of virus-stimulated cytokine in brain functions, but also the potential molecular mechanisms that underlie it. With such high activation of ISGs in the hippocampus and cerebellum (Figure 5 ), brain regions that are highly involved in learning/memory, emotion and other cognitive functions, 47, 48 further study of the neurochemical and neurohistological impact of these two areas by IFN-a may shed light on the neurobiology of human neuropsychiatric disorders.
In addition to the well-characterized JAK/STAT pathway for IFN-a signaling, recent work to elucidate the cellular responses to IFN-a has identified other signaling pathways in the post-receptor signal cascade in vitro. 49 The two major alternative pathways include STAT1-independent phosphoinositide 3 kinase (PI3K) 50 and mitogen-activated protein (p38 MAP) kinase 51 pathways. However, the present study clearly revealed the STAT1 dependence of the transcriptional response to IFN-a in vivo (Figure 7 ), which indicates that there is little, if any, role for alternative pathway signaling in response to IFN-a. This is consistent with previous reports in which STAT1 knockout mice were observed to be extremely sensitive to viruses and microbial pathogens. 52, 53 As these JAK/STAT1-independent pathways for IFN-a signaling were identified based solely on studies using cancer or immortalized cell lines, 49 which may already bear abnormality of cellular machinery, the physiological and pathophysiological significance of these recently discovered alternative pathways in IFN-a signaling remains to be further defined in vivo. In a recent study, we did not detect any difference of either phospho-p38 MAPK or total p38 MAPK at the protein level by western blot in the brains of GFAP-IFNa transgenic mice compared with wild-type controls. 35 Considerable controversy remains on the neurochemical and neurobehavioral effects of IFN-a treatment, and in efforts to establish appropriate animal models for its use to explore the cellular and molecular basis for IFN-a-induced neuropsychiatric illnesses. Besides the treatment regimen involving doses of IFN-a applied and the duration of the treatment, most previous studies used human IFN-a instead of homologous IFN-a for their studies in rodents. 13, 54, 55 Our results revealed that human IFN-a as used in previous studies in rodents, 13, 55 did not have similar transcriptional action in mice, which indicates the importance of using homologous IFN-a in animal studies. 33 This may, at least in part, explain the negative results reported frequently in rodents when human IFN-a preparations were utilized. 55, 56 In addition, measuring IFN-stimulated genes or gene products can serve as an indicator not only for IFN-a action, but also for the bioactivity of IFN-a protein used. This is because IFN-a bioactivity (in units quantified by its protection of virus-induced cell damage in vitro) may vary significantly in different preparations, including those derived from freezethawing cycles.
In summary, our present data revealed a direct action in the brain by systemic IFN-a. Following i.p. IFN-a, brain parenchyma cells, in particular neurons, respond with dramatic activation of IFN-regulated gene expression, indicating highly sensitive cell populations to IFN-a in the CNS, and highlighting the potential roles of IFN-a in brain physiology and CNS disorders. We also demonstrate a critical role of the JAK/STAT pathway for IFN-a biology in vivo. With increased interest in IFN-a in human neuropsychiatric/neurological disorders, our study offers a rodent model useful in the search for the cellular and molecular basis of IFN-a-induced CNS abnormalities.
